SOLX Titanium Sapphire Laser for Trabeculoplasty
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L5L 1W8
- Credit Valley Eyecare
-
-
Quebec
-
Montréal, Quebec, Canada, H1V 1G5
- Institut du Glaucome de Montréal
-
-
-
-
-
Tel Aviv, Israel, 64239
- Sourasky Medical Center
-
Tel Hashomer, Israel, 52621
- Sheba medical center
-
-
-
-
-
Madrid, Spain, 28040
- Hospital Clínico San Carlos de Madrid
-
-
-
-
California
-
Petaluma, California, United States, 94954
- North Bay Eye Associates
-
-
Florida
-
Tampa, Florida, United States, 33603
- International Eye Care
-
-
New York
-
New York, New York, United States, 10003
- Glaucoma Associates of New York
-
-
Texas
-
Austin, Texas, United States, 78705
- Texan Eye Care
-
Houston, Texas, United States, 77002
- Mann Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:Clinical Diagnosis of Open Angle Glaucoma
- Patient is aged 18 years or older, with 2 sighted eyes.
- Eye to be treated have average IOP greater or equal to 22 mmHg, measured at 2 pretreatment visits.
- Eye to be treated either exhibits:
- poorly controlled open angle glaucoma and on maximal tolerated medical therapy
- OR poorly controlled open angle glaucoma and failed previous laser trabeculoplasty (180° available to treat if previous ALT; can treat over previous SLT)
Exclusion Criteria:
Patients are not eligible for enrollment if any of the following exclusion criteria are met:
Eye to be treated has any of the following:
- evidence of glaucoma other than open-angle glaucoma;
- severe paracentral or generalized field defect;
- any ocular condition that precluded adequate visualization and treatment of the trabecular meshwork.
- prior glaucoma surgery other than laser trabeculoplasty or peripheral iridotomy.
- Patient has mental impairment such that he/she could not understand the protocol or is not in a position to provide written informed consent.
- Patient is pregnant.
- Patient might require other ocular surgery within the 6-month follow-up period.
- Patient has a medical history that suggested the potential for complications from TiSaLT.
- Having concurrent treatment with systemic steroids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: 1
Titanium sapphire laser treatment
|
Spot laser treatment, ~50 spots over 180°
|
|
ACTIVE_COMPARATOR: 2
Argon laser treatment
|
Spot laser treatment, ~50 spots over 180°
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intraocular Pressure (IOP)
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse event frequency
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Jan S Peterson, MS, RAC, The Emmes Company, LLC
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SLX41
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.